Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2005 Aug;54(8):1121-5.
doi: 10.1136/gut.2004.049460.

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

A Kandiel  1 , A G Fraser, B I Korelitz, C Brensinger, J D Lewis
Affiliations
Meta-Analysis

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

A Kandiel et al. Gut. 2005 Aug.

Abstract

Background: Inflammatory bowel disease (IBD) is commonly treated with immunomodulators such as azathioprine and 6-mercaptopurine (6-MP). Studies examining lymphoma risk in IBD patients treated with these medications have been underpowered and have yielded conflicting conclusions.

Aims: The purpose of this meta-analysis was to provide a more precise estimate of the relative risk of lymphoma among IBD patients treated with azathioprine or 6-MP.

Methods: Studies were included if they were English language, full article, cohort studies specifically designed to evaluate cancer as an adverse outcome of treatment with azathioprine or 6-MP. Pooled standardised incidence ratios were calculated to estimate the relative risk of lymphoma associated with therapy. Heterogeneity was assessed using Poisson regression. Sensitivity analyses examined the influence of individual studies on risk estimate and heterogeneity statistics.

Results: Six studies were identified that met our inclusion criteria. When the data were combined across all studies, the pooled relative risk was 4.18 (95% confidence interval 2.07-7.51; 11 observed cases, 2.63 expected). Sensitivity analysis showed that exclusion of any one study had a relatively small effect on the pooled relative risk estimate (range 3.49-5.21) but excluding either the study with the highest or lowest estimated relative risk eliminated the statistically significant heterogeneity.

Conclusions: Our data suggest an approximate fourfold increased risk of lymphoma in IBD patients treated with azathioprine/6-MP. The increased risk of lymphoma could be a result of the medications, the severity of the underlying disease, or a combination of the two.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Heterogeneity among the studies. Relative risk of lymphoma against the expected number of cases of lymphoma in each study. The expected number of cases was strongly correlated with total follow up time for the cohort. There was a lower estimated relative risk among large studies and higher estimates among smaller studies.
See this image and copyright information in PMC

Comment in

References

    1. Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001;121:1080–7. - PubMed
    1. Ekbom A, Helmick C, Zack M, et al. Extracolonic malignancies in inflammatory bowel disease. Cancer 1991;67:2015–19. - PubMed
    1. Karlen P, Lofberg R, Brostrom O, et al. Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am J Gastroenterol 1999;94:1047–52. - PubMed
    1. Persson PG, Karlen P, Bernell O, et al. Crohn’s disease and cancer: a population-based cohort study. Gastroenterology 1994;107:1675–9. - PubMed
    1. Loftus E, Tremaine W, Habermann T, et al. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 1998;95:2308–12. - PubMed

Publication types

MeSH terms